Speaker(s): 

David Frank, PhD, Staff Member, New York University - has nothing to disclose.

Moderator(s): 

Katrina Romagnoli, Staff Member, Geisinger - has nothing to disclose.   

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• To describe an alternative to the institutional view of methadone maintenance treatment as a treatment for addiction.
• To use qualitative and quantitative evidence to show a misalignment between how MMT is delivered and the treatment needs and goals of many patients.
• To outline potential strategies for improving MMT and to illustrate how such changes could impact harms associated with drug use, particularly overdose.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, Ed.D., BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH; Lisabeth Karetsky, CPhT and Nichole Varela Gonzalez have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.